Clearance of Vykat unlocks what analysts anticipate will be a lucrative market opportunity for Soleno Therapeutics.
The approval was based on a comprehensive clinical data package, which included a single phase 1 trial and a phase 3 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback